Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1160 (LINC01160) is a long non-coding RNA (lncRNA) transcribed from intergenic regions of the human genome, meaning it does not overlap any protein-coding genes[1][3][5][7]. LINC01160 is categorized as a lincRNA, a subclass of lncRNAs generally over 200 nucleotides in length that act by regulating gene expression, often through epigenetic or transcriptional mechanisms[5][7]. Unlike some characterized lincRNAs, there is currently no direct evidence that LINC01160 is linked to specific biological processes or diseases, nor is it recognized as a therapeutic target or biomarker[1][3]. Also, there are no known drugs or safety concerns associated with LINC01160. Its aliases include NONHSAG002414.2 and HSALNG0006063, and it is annotated in several genomic reference databases[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1160 (LINC01160).